Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES‑1 gene expression and H3K27me3 demethylation

Xu,Zhenshu; Xiong,Donglian; Zhang,Jushun; Zhang,Jingyan; Chen,Xiuli; Chen,Zhizhe; Zhan,Rong

doi:10.3892/ol.2017.7450

Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES‑1 gene expression and H3K27me3 demethylation

Authors:
- Zhenshu Xu
- Donglian Xiong
- Jushun Zhang
- Jingyan Zhang
- Xiuli Chen
- Zhizhe Chen
- Rong Zhan
View Affiliations

Affiliations: Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: November 21, 2017 https://doi.org/10.3892/ol.2017.7450
Pages: 1937-1942

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The majority of patients with chronic lymphocytic leukemia (CLL) are not cured by traditional chemotherapy. One possible explanation for this is that the microenvironment protects CLL cells from both spontaneous‑ and cytotoxic‑mediated apoptosis. The present study was designed to investigate the mechanisms accounting for these effects, since this information is crucial to understanding CLL physiopathology and identifying potential treatment targets. The CLL cell line L1210 and primary CLL cells were cultured under different conditions: With serum, cyclophosphamide (CTX), or with monolayers and conditioned medium (CM) from the stromal cell line HESS‑5. Apoptosis, Hes family BHLH transcription factor 1 (HES‑1) gene and protein expression, and histone H3K27me3 DNA demethylation were determined. Co‑culture of L1210 cells with HESS‑5 cells significantly inhibited serum deprivation‑ and CTX‑induced apoptosis of leukemia cells, and resulted in a significant increase in short‑term proliferation. Soluble factors in the CM from HESS‑5 cells had a negligible effect. The HESS‑5 cell‑mediated inhibition of apoptosis of CLL cells was associated with increased HES‑1 expression and hypomethylation of the H3K27me3 gene in the leukemia cells. These results indicate that stromal cells enhance the survival of CLL cells by regulating the HES‑1 gene and protein expression, as well as H3K27me3 DNA demethylation, and suggest that specific interactions between stromal and leukemia cells may enhance the resistance of leukemia cells to chemotherapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Suresh T, Lee L, Joshi J and Barta S: New antibody approaches to lymphoma therapy. J Hematol Oncol. 7:582014. View Article : Google Scholar : PubMed/NCBI
3	Wu J, Fu J, Zhang M and Liu D: Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 8:1042015. View Article : Google Scholar : PubMed/NCBI
4	Nwabo Kamdje AH and Krampera M: Notch signaling in acute lymphoblastic leukemia: Any role for stromal microenvironment. Blood. 118:6506–6514. 2011. View Article : Google Scholar : PubMed/NCBI
5	Burger JA, Ghia P, Rosenwald A and Caligaris-Cappio F: The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood. 114:3367–3375. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sun Z, Wang S and Zhao RC: The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 7:142014. View Article : Google Scholar : PubMed/NCBI
7	Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, et al: Bi-directional activation between mesenchymal stem cells and CLL B-cells: Implication for CLL disease progression. Br J Haematol. 147:471–483. 2009. View Article : Google Scholar : PubMed/NCBI
8	Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N, Ajchenbaum-Cymbalista F and Ledoux D: Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res. 69:6387–6395. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, et al: SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 365:2497–2506. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xu ZS, Zhang JS, Zhang JY, Wu SQ, Xiong DL, Chen HJ, Chen ZZ and Zhan R: Constitutive activation of NF-kB signaling by NOTCH1 mutation in chronic lymphocytic leukemia. Oncol Rep. 33:1609–1614. 2015. View Article : Google Scholar : PubMed/NCBI
11	Ross J, Mavoungou L, Bresenick EH and Milot E: GATA-1 utilizes lkaros and polycomb repressive complex 2 to suppress Hes-1 and to promote erythropoiesis. Mol Cell Biol. 32:3624–3638. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hasslen SR, Burns AR, Simon SL, Smith CW, Starr K, Barclay AN, Michie SA, Nelson RD and Erlandsen SL: Preservation of spatial organization and antigenicity of leukocyte surface molecules by aldehyde fixation: Flow cytometry and high-resolution FESEM studies of CD62L, CD11b and Thy-1. J Histochem Cytochem. 44:1115–1122. 1996. View Article : Google Scholar : PubMed/NCBI
13	Chomozynski P and Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
14	Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX and Xie D: High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse worse prognosis in patients. Mol Med. 17:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B and Furukawa Y: Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest. 125:4375–4390. 2015. View Article : Google Scholar : PubMed/NCBI
16	Amin S, Walsh M, Wilson C, Parker AE, Oscier D, Willmore E, Mann D and Mann J: Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. J Cell Mol Med. 16:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
17	Moshaver B, van der Pol MA, Westra AH, Ossenkoppele GJ, Zweegman S and Schuurhuis GJ: Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect acute myeloid leukemia cell survival. Leuk Lymphoma. 49:134–148. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lagneaux L, Delforge A, Bron D, De Bruyn C and Stryckmans P: Chronic lymphocytic leukemic B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 91:2387–2396. 1998.PubMed/NCBI
19	Shimakura Y, Kawada H, Ando K, Sato T, Nakamura Y, Tsuji T, Kato S and Hotta T: Murine stromal cell line HESS-5 maintains reconstituting ability of ex vivo-generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood. Stem Cells. 18:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
20	Roberts RA, Spooncer E, Parkinson EK, Lord BI, Allen TD and Dexter TM: Metabolically inactive 3T3 cells can substitute for marrow stromal cells to promote the proliferation and development of multipotent hematopoietic stem cells. J Cell Physiol. 132:203–214. 1987. View Article : Google Scholar : PubMed/NCBI
21	Jiang H, Sugimoto K, Sawada H, Takashita E, Tohma M, Gonda H and Mori KJ: Mutual education between hematopoietic cells and bone marrow stromal cells through direct cell-to-cell contact: Factors that determine the growth of bone marrow stroma-dependent leukemic (HB-1) cells. Blood. 92:834–841. 1998.PubMed/NCBI
22	Smith AD, Roda D and Yap TA: Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 7:702014. View Article : Google Scholar : PubMed/NCBI
23	Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao S, Xu J, Zhu X, Yuan W, Cheng T and Zheng G: Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen. J Hematol Oncol. 7:712014. View Article : Google Scholar : PubMed/NCBI
24	Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, et al: Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med. 208:1389–1401. 2011. View Article : Google Scholar : PubMed/NCBI
25	Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y and Croce CM: NOTCH1 mutations in CLL associated with trisomy 12. Blood. 119:329–331. 2012. View Article : Google Scholar : PubMed/NCBI
26	Xu Z, Zhang J, Wu S, Zheng Z, Chen Z and Zhan R: Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China. Oncol Lett. 5:1266–1272. 2013.PubMed/NCBI
27	Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, Matis S, Grazia Recchia A, Gigliotti V, Gentile M, et al: Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics. 6:188–194. 2011. View Article : Google Scholar : PubMed/NCBI
28	Martín-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, et al: New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 113:2488–2497. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee YM, Chiao JW and Liu DL: Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol. 1:62008. View Article : Google Scholar : PubMed/NCBI